In this study, we demonstrate that the therapeutic outcome of the ICV administration of nusinersen (Spinraza) in the SMNΔ7 mouse model of type I SMA is mediated by the selective restoration of SMN levels in the spinal cord but not in muscle. The gene discussed is SMN2; the disease is spinal muscular atrophy, type 1.